HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fowler, J. S. Articles by Vaska, P. Search for Related Content PubMed PubMed Citation Articles by Fowler, J. S. Articles by Vaska, P.

Comparison of Monoamine Oxidase A in Peripheral Organs in Nonsmokers and Smokers

¹ Chemistry Department, Brookhaven National Laboratory, Upton, New York
² Medical Department, Brookhaven National Laboratory, Upton, New York
³ National Institute on Drug Abuse, Bethesda, Maryland
⁴ Department of Applied Mathematics and Statistics, State University of New York at Stony Brook, Stony Brook, New York
⁵ Department of Radiology, State University of New York at Stony Brook, Stony Brook, New York

Smokers have reduced levels of brain monoamine oxidase A (MAO A) leading to speculation that MAO A inhibition by tobacco smoke may underlie some of the neurophysiologic effects of smoking. Because smoking exposes peripheral organs as well as the brain to MAO A–inhibitory compounds, we determined whether smokers would also have reduced MAO A in peripheral organs. Methods: We measured MAO A in peripheral organs in a group of 9 smokers and compared it with a group of nonsmokers studied previously. MAO A was measured using PET and serial scans with the MAO A–specific radiotracers ¹¹C-clorgyline and deuterium-substituted ¹¹C-clorgyline (¹¹C-clorgyline-D2) using the deuterium isotope effect to assess binding specificity. The time course of radiotracer in the arterial plasma was also measured and data from the tissue time–activity curves and the arterial input function were analyzed using a 3-compartment model to estimate k₃, which represents the rate-limiting step for the irreversible binding of labeled clorgyline to MAO A. Results: Tracer uptake at plateau was reduced with deuterium substitution for the heart, lungs, and kidneys, indicating specificity for MAO. There was no difference in organ uptake at plateau between nonsmokers and smokers though, for the smokers, the efflux of tracer from peak uptake to plateau was slower for the lungs. The area under the time–activity curve for the arterial plasma was also significantly reduced for smokers versus nonsmokers and the reduction occurred in the first few minutes after radiotracer injection. Smokers had an 50% reduction in k₃ when compared with nonsmokers; however, k₃ did not differ for nonsmokers and smokers for the heart and the kidneys. Conclusion: Because MAO A breaks down serotonin, norepinephrine, dopamine, and tyramine, and because the lung is a major metabolic organ in degrading some of these substances, reduced lung MAO A may contribute to some of the physiologic effects of smoking. This study also revealed that the concentration of the radiotracers in the arterial plasma is significantly lower for the smoker versus the nonsmoker and that this appears to be caused in part by retention of the radiotracer in lungs. If this is generally true for other substances that are administered intravenously, then this needs to be considered as a variable that may contribute to different short-term behavioral responses to intravenously administered drugs for nonsmokers versus smokers.

Key Words: PET • cigarette smoke • monoamine oxidase • lung • arterial plasma

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  

This article has been cited by other articles:

				R. M. Baldwin Imaging MAO-A Levels by PET Using the Deuterium Isotope Effect J. Nucl. Med., September 1, 2005; 46(9): 1411 - 1413. [Full Text] [PDF]